SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001819790-23-000075
Filing Date
2023-09-19
Accepted
2023-09-19 16:25:56
Documents
3
Period of Report
2023-09-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1695155145.html 4  
1 FORM 4 wk-form4_1695155145.xml 4 5483
2 EX-24 a2023-05x21secpoascottmo.htm EX-24 644
3 a2023-05x21secpoascottmo001.jpg GRAPHIC 223378
  Complete submission text file 0001819790-23-000075.txt   315304
Mailing Address C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT SUITE 101 SOUTH SAN FRANCISCO CA 94080
Business Address
Morrison Scott W (Reporting) CIK: 0001662426 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 231264161

Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)